vault nanocapsules as adjuvants favor cell-mediated over antibody-mediated immune responses following immunization of mice拱顶nanocapsules作为佐剂支持细胞介导抗体介入后免疫小鼠的免疫反应.pdfVIP

Vault Nanocapsules as Adjuvants Favor Cell-Mediated over Antibody-Mediated Immune Responses following Immunization of Mice 1. 2. 2 2 3 Upendra K. Kar , Janina Jiang , Cheryl I. Champion , Sahar Salehi , Minu Srivastava , Sherven Sharma3, Shahrooz Rabizadeh4,5, Kayvan Niazi4,5, Valerie Kickhoefer1,5, Leonard H. Rome1,5, Kathleen A. Kelly2,5* 1 Department of Biological Chemistry, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, United States of America, 2 Department of Pathology and Lab Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, United States of America, 3 Molecular Medicine Laboratory, Veteran’s Affairs Greater Los Angeles Healthcare System, Los Angeles, California, United States of America, 4 Department of Bioengineering, Samueli School of Engineering, University of California Los Angeles, Los Angeles, California, United States of America, 5 California NanoSystems Institute, University of California Los Angeles, Los Angeles, California, United States of America Abstract Background: Modifications of adjuvants that induce cell-mediated over antibody-mediated immunity is desired for development of vaccines. Nanocapsules have been found to be viable adjuvants and are amenable to engineering for desired immune responses. We previously showed that natural nanocapsules called vaults can be genetically engineered to elicit Th1 immunity and protection from a mucosal bacterial infection. The purpose of our study was to characterize immunity produced in response to OVA within vault nanoparticles and compare it to another nanocarrier. Methodology and Principal Findings: We cha